Cheng-Zhong Zhang

Assistant Professor

Dana-Farber Cancer Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Motivation Single cell RNAseq (scRNAseq) is an ideal tool to characterize the heterogeneity within the tumor microenvironment, however, accurate identification of tumor cells can be a challenge. Reference-based methods can be inaccurate, if reference datasets are even available. Current purpose-built methods can be inaccurate, particularly with highly heterogeneous tumor types. Improved methods are needed. We explored the use of genetic variants to distinguish tumor from normal cells within scRNAseq data. Results We characterized the limitations inherent to calling variants from scRNAseq data, quantifying how data sparsity precludes genetic distance calculation between single cells. As a novel workaround, we pooled data from transcriptionally similar cell clusters to call high quality variants and then calculated pairwise differences between cell populations and performed hierarchical clustering. We quantified confidence in genetic divergence between tumor and normal cell populations using bootstrapping. We performed extensive validation to assess accurate identification of tumor cells using ground-truth datasets. Application of our method to human scRNAseq samples highlighted the utility of our approach and revealed how mutational burden influences successful tumor cell identification. Improved cell type assignment in scRNAseq data will facilitate analysis of tumor samples and, in turn, accelerate our understanding of the mechanisms underlying tumor progression and reveal potential biological vulnerabilities that can be exploited to develop improved treatment options. Availability and implementation Our method is publicly available as an R package: SCANBIT (Single Cell Altered Nucleotide Based Inference of Tumor) https://github.com/kidcancerlab/scanBit .

Year:

2026

Ionizing radiation (IR) is widely used in cancer therapy, yet the mechanisms by which IR-induced DNA damage translates into delayed proliferative death and secondary malignancy risk remain incompletely defined. Radiation generates double-strand breaks (DSBs) that are frequently misrepaired, giving rise to micronuclei and chromosome bridges—abnormal nuclear structures known to drive chromosomal instability. Here, a modified live-cell imaging and single-cell whole-genome sequencing (WGS) approach was used to directly connect early cytological responses to genome-wide outcomes in cells exposed to graded IR doses. Tracking asynchronously cycling cells revealed that micronuclei, chromosome bridges, and nuclear fragmentation form at high frequency during the first mitosis after irradiation, in a strongly cell-cycle–dependent manner: micronuclei were most frequent after S-phase irradiation, whereas chromosome bridges predominated when damage occurred in G1 or S phase. Lineage tracing combined with clonogenic assays showed that formation of abnormal nuclear structures in the first post-irradiation division is a major determinant of long-term proliferative capacity, with centromere-containing (centric) fragments and bridges exerting a stronger anti-proliferative effect than acentric micronuclei. Single-cell WGS of daughter and granddaughter cells demonstrated that these structures generate reciprocal copy-number changes, clustered rearrangements, and chromothripsis-like events that are largely incompatible with sustained proliferation. In contrast, bulk WGS of surviving single-cell–derived clones revealed only modest increases in single-nucleotide variants and indels but an enrichment of nonhomologous end-joining–associated deletion signatures and selected structural variants, including amplification of a pre-existing 12p gain. These findings identify abnormal nuclear structures as key intermediates linking IR-induced DNA lesions to mitotic catastrophe and provide insight into selective tolerance of specific rearrangements.

Year:

2025

Renal cell carcinomas comprise multiple molecularly distinct cancers but most are treated empirically with therapies designed for clear cell RCC (ccRCC), the most common subtype, due to incomplete understanding of subtype-specific biology. We analyzed single-cell transcriptomes and chromatin accessibility profiles from translocation renal cell carcinoma (tRCC), an aggressive RCC defined by oncogenic TFE3 gene fusions. Unexpectedly, despite arising from a proximal tubule cell of origin similar to ccRCC, tRCCs display markedly distinct oncogenic programs and an immunosuppressive tumor microenvironment. tRCCs exhibit six conserved tumor meta-programs, including epithelial-mesenchymal transition and proximal tubule identity programs whose balance is regulated by TFE3 fusion activity. The fusion-driven EMT program drives a suppressive TME marked by progenitor-exhausted CD8+ T cells, anti-inflammatory SPP1+ macrophages, and matrix-associated fibroblasts (mCAFs). Our findings highlight unique TFE3 fusion-driven biology in tRCC, explaining its reduced immunotherapy responsiveness relative to ccRCC, and suggesting strategies for targeting fusion-driven oncogenic programs and TME reprogramming.

Year:

2025

DNA rearrangements are thought to arise from two classes of processes. The first class involves DNA breakage and fusion (“cut-and-paste”) without net DNA gain or loss. The second class involves aberrant DNA replication (“copy-and-paste”) and can produce either net DNA gain or loss. We previously demonstrated that the partitioning of chromosomes into aberrant structures of the nucleus, micronuclei or chromosome bridges, can generate cut-and-paste rearrangements by chromosome fragmentation and ligation. Surprisingly, in the progeny clones of single cells that have undergone chromosome bridge breakage, we identified large segmental duplications and short sequence insertions that are commonly attributed to copy-and-paste processes. Here, we demonstrate that both large duplications and short insertions are inherent outcomes of the replication and fusion of unligated DNA ends, a process we term breakage-replication/fusion (B-R/F). We propose that B-R/F provides a unifying explanation for complex rearrangement patterns including chromothripsis and chromoanasynthesis and enables rapid DNA amplification after chromosome fragmentation.

Year:

2024

Genomic characterization has revealed widespread structural complexity in cancer karyotypes, however shotgun sequencing cannot resolve genomic rearrangements with chromosome-length continuity. Here, we describe a two-tiered approach to determine the segmental composition of rearranged chromosomes with haplotype resolution. First, we present refLinker , a new method for robust determination of chromosomal haplotypes using cancer Hi-C data. Second, we use haplotype-specific Hi-C contacts to determine the segmental structure of rearranged chromosomes. By contrast with existing methods for diploid haplotype inference, our approach is robust to the confounding effects of large-scale DNA deletions, duplications, and high-level amplification in cancer sequencing. Using this approach, we examine haplotype-specific expression changes on rearranged homologs and provide direct evidence for long-range transcriptional activation and repression associated with rearrangements of the inactive X chromosome (Xi). Together, these results reveal the significant transcriptional consequences of somatic Xi rearrangements, highlighting refLinker ’s broad utility for studying the functional consequences of chromosomal rearrangements.

Year:

2024

Collaborators (5)

Eliezer Van Allen

Professor

Harvard University

UNITED STATES
View details

Srinivas Viswanathan

Dana-Farber Cancer Institute

UNITED STATES
View details

Toni Choueiri

Director, Lank Center for Genitourinary Oncology

Dana-Farber Cancer Institute

UNITED STATES
View details

James Reinecke

Assistant professor

Nationwide Children's Hospital

UNITED STATES
View details

Ryan Roberts

Principal Investigator

Nationwide Children's Hospital

UNITED STATES
View details